[Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].

In a multicentre study a total of 113 patients suffering from disturbed blood flow conditions of the lower extremities (type II Fontaine) were treated with butalamine hydrochloride tablets, each containing 80 mg of the active principle. In 96% of the cases given a daily dose of 3 x 2 tablets and in 82% of those treated with a daily dose of 3 x 1 tablet both subjective and objective clinical symptoms, such as walking distance and Ratschow's testing parameters, were found to be improved. In view of the findings that metabolic functions as well as systemic blood flow conditions were not affected and that the drug was furthermore well tolerated by the gastrointestinal system, butalamine hydrochloride proved to be an effective therapeutic in long-term treatment of patients suffering from blood flow disorders of the lower extremities.
AuthorsH Kling
JournalFortschritte der Medizin (Fortschr Med) Vol. 97 Issue 19 Pg. 926-8 (May 17 1979) ISSN: 0015-8178 [Print] GERMANY, WEST
Vernacular TitlePharmakotherapie chronisch arterieller Verschlusskrankheiten der unteren Extremitäten mit Butalamin-HCl.
PMID109382 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Oxadiazoles
  • Arterial Occlusive Diseases (drug therapy)
  • Drug Evaluation
  • Female
  • Humans
  • Leg (blood supply)
  • Male
  • Oxadiazoles (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: